CRAVACIN® 6 mg Tablet
Secure Your Supply of the Selective TYK2 Inhibitor. High Quality. High Value.
Partner with Everest Pharmaceuticals Ltd. for a reliable and cost-effective source of Deucravacitinib—the targeted oral therapy for moderate-to-severe plaque psoriasis.
Composition
Each film-coated tablet contains Deucravacitinib INN 6 mg.
Indication
Cravacin is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent. immunosuppressants.
Dose and Administration
The recommended dosage of Cravacin is 6 mg taken orally once daily, with or without food. Do not crush, cut, or chew the tablets.
Pharmacology
Deucravacitinib is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family. It binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and catalytic domains, which results in allosteric inhibition of receptor-mediated activation of TYK2.
Contraindication
Cravacin is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in Cravacin.
Most common side effects include:
common cold, sore throat, and sinus infection (upper respiratory infections), cold sores (herpes simplex), canker sores, inflamed hair pores (folliculitis), and acne.
Serious side effects may include allergic reactions like angioedema (swelling in the face, eyelids, lips, tongue, or throat) or trouble breathing.
Warning
- Hypersensitivity: Reactions such as angioedema have been reported.
- Infections: May increase the risk of infection; avoid use in patients with active or serious infection. Tuberculosis: Evaluate for TB prior to initiating treatment.
- Malignancy: Malignancies, including lymphomas, were observed in clinical trials. Immunizations: Avoid use with live vaccines.
- Potential Risks Related to JAK Inhibition: Higher rates of all-cause mortality, major adverse cardiovascular events, and overall thrombosis were observed in patients treated with a JAK inhibitor (though Cravacin is not approved for use in Rheumatoid Arthritis).
Use in Pregnancy and Lactation
- Pregnancy: Data is insufficient to evaluate a drug-associated risk of major birth defects or adverse outcomes.
- Lactation: The benefits of breastfeeding should be weighed against the mother’s clinical need for Cravacin and any potential adverse effects on the breastfed infant.
Hepatic Impairment
Not recommended in patients with severe hepatic impairment (Child-Pugh C). No dosage adjustment is needed for mild to moderate hepatic impairment.
Renal Impairment
No dose adjustment is recommended for patients with mild, moderate, or severe renal impairment or ESRD on dialysis.
Everest Pharmaceuticals Ltd. FDA-Approved Deucravacitinib Generic Manufacturer & Supplier
We ensure every Cravacin 6 mg tablet meets stringent global standards.
Order Now
Request a Volume Quote and Start Your Partnership.
The High-Value Generic Alternative to SOTYKTU™ (Deucravacitinib)
CRAVACIN® contains the same active drug, Deucravacitinib, offering the identical mechanism of action (selective TYK2 inhibition) for proven clinical results.
Mechanism of Action
Cravacin is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2), a key regulator in the inflammatory pathways of psoriasis. Its selective action provides a clear scientific rationale for its clinical use.
Indication and Dosing
Cravacin is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2), a key regulator in the inflammatory pathways of psoriasis. Its selective action provides a clear scientific rationale for its clinical use.
Important Safety Information (ISI):
The use of Cravacin requires adherence to professional medical guidance. Patients should be screened for Tuberculosis (TB) prior to initiation. Cravacin is not recommended for use with live vaccines or in combination with other potent immunosuppressants.
Global Sales & Export
We invite distribution and licensing partners to collaborate on expanding the global accessibility of this high-value, FDA-approved generic.